



Source

Biotinylated Anti-Cetuximab Antibody (AY31) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

Clone

AY31

Species

Mouse

Isotype

Mouse IgG1 | kappa

Antibody Type

Hybridoma Monoclonal

Reactivity

Human

Immunogen

Cetuximab.

Specificity

Recognizes Cetuximab specifically.

Application

Application	Recommended Usage
ELISA	0.5-200 ng/mL

Purity

>90% as determined by SDS-PAGE.

Purification

Protein A purified/ Protein G purified

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- 4-8°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.

SDS-PAGE



Biotinylated Anti-Cetuximab Antibody (AY31) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the



Discounts, Gifts,
and more!






protein is greater than 90%.

Bioactivity-ELISA



Immobilized Anti-Cetuximab Antibody (12B1E9) (Cat. No. CEB-Y29c) at 2 µg/mL, add increasing concentrations of Cetuximab and then add Biotinylated Anti-Cetuximab Antibody (AY31) (Cat. No. CEB-BY31) at 1 µg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4.84 ng/mL (QC tested).

Immobilized cetuximab at 0.1 µg/mL (100 µL/well) can bind Biotinylated Anti-Cetuximab Antibody (AY31) (Cat. No. CEB-BY31) with a linear range of 0.39-25 ng/mL.



ELISA analysis shows that the binding of cetuximab to Human EGF R, His Tag (Cat. No. EGR-H5222) was inhibited by increasing concentration of Biotinylated Anti-Cetuximab Antibody (AY31) (Cat. No. CEB-BY31). The concentration of cetuximab used is 3 ng/mL.

Background

Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFR monoclonal antibody specific for the N-terminal portion of human EGFR with human IgG1 heavy and kappa light chain constant (framework) regions.

Clinical and Translational Updates

Discounts, Gifts,
and more!

